Melt Pharmaceuticals is led by a management team with extensive pharmaceutical industry experience and a track record of success in drug development and commercialization.

Greg Madison

Chief Executive Officer

Mr. Madison is a 30-year pharmaceutical industry veteran, with strong operating experience leading small to medium size organizations. Prior to leading Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals, where he led the company transformation from small, development stage to a fully integrated, commercial-stage company in less than twelve months leading to the companies first US launch. He drove strong revenue growth, raised significant capital to fund operations, and oversaw approvals in the EU as well as a label expansion in the US as the first ever oral product to treat iron deficiency anemia, ultimately leading to a merger with Akebia Therapeutics. In 2013, he was Chief Commercial Officer at AMAG pharmaceuticals where his team had record revenue earnings, and overhauled their contracting strategy. From 2000-2012, Mr. Madison was at Genzyme Corporation in a variety of commercially focused roles, ultimately serving as Vice President and General Manager of Nephrology Division. He played a crucial role in the world-wide development and growth of Renagel/Renvela as the world’s leading phosphate binder with revenues exceeding $1 billion prior to his departure. Mr. Madison served in leadership roles in sales management, reimbursement, distribution, and marketing while at Genzyme and began his career as a sales representative for Janssen Pharmaceutica, a division of Johnson and Johnson. Mr Madison serves on the Board of Trustees for the American Kidney Fund, the nations largest non-profit organization for people with kidney disease.

Mark Hazard

Chief Technical Officer

Mr. Hazard is an experienced leader in pharmaceutical product development, quality and manufacturing. As a distinguished pharmaceutical professional, he brings expertise in biotechnology, regulatory, quality and supply chain logistics. Mr. Hazard imparts effectiveness and confidence to Melt Pharmaceuticals with over 30 years of experience in the pharmaceutical sector.

Most recently, he served as the Vice President of CMC and Head of Quality Operations at Akebia Therapeutics. In this role he was responsible for all aspects of manufacturing and quality for a single commercial small molecule product. Before that, Mr. Hazard served as the Vice President of Upstream Manufacturing for Synageva Biopharma. His responsibilities included developing and enhancing upstream manufacturing, supply chain and quality. While at Synageva, he was an integral part of successfully attaining approval for multiple facilities to manufacture and supply a novel therapeutic protein as well as the ultimate approval of the product in the United States, Europe, and Japan. Mr. Hazard formerly held positions of increasing responsibility in quality operations and manufacturing at Pfizer in a career spanning 22 years. Mr. Hazard holds a Bachelor of Science degree in Chemistry and a Master of Science degree focusing on management.